

arm research

outperform

LAKSHMI OVERSEAS — RESULT UPDATE

29th January, 2010

STOCK DETAILS

519570
Rs. 138.4/-
Rs. 8,745 mn
Rs. 2/-
Rs. 89/-
Rs. 201.50 (29th Jan 2009)
Rs. 61.55 (14 th May 2009)
F F

NOTE: Company is following Oct - Sep as a Financial Year

(Rs. in mn)

Particulars	Q1 FY 10	Q1 FY 09	YoY % change	Q4 FY 09	QoQ % change	FY 09	FY 08 (18 months)
Net Sales	2,030	1,769	14.7%	1,872	8.44%	6,944	16,048
EBITDA	490	452	8.4%	620	(21%)	2,213	3,250
Margins (%)	24%	26%	(7.6)%	33%	(27%)	32%	20%
Depreciation	89	61	45.9%	43	107%	304	337
Interest	140	128	9.35%	157	(11%)	638	496
Other	-	-	-	1.2	(100%)	6	9.42
Income							
PBT	261	263	(0.76)%	421	(38%)	1265	2426
Tax	24	88		100		341	809
PAT	237	175	35%	321	(26%)	924	1,617
Margins (%)	12%	10%	20%	17%		13%	10%
No. of Equity	63.19	63.19		63.19	63.19	63.19	63.19
Shares (mn)							
FV (Rs.)	2	2	-	2	-	2	2
EPS	3.75	2.76	35.8%	5.08	(36%)	14.62	25.58



arm research

outperform

Q1 FY 10 Result analysis

- 1) Growth in Net Sales: Net sales of the company improved by $\sim 15\%$ YoY to Rs. 2,030 mn in Q1FY 10 on account of higher volumes.
- **2) EBITDA:** Growth of 8.4% was seen in EBITDA of Q1FY 10 on YoY basis. The growth in EBITDA can be partially attributed to high pricing power enjoyed due to shortage of non basmati rice in the country.
- **3) YoY growth in Net Profits:** Net profit of the company has increased from Rs. 175 mn to Rs. 237 mn in Q1 FY 10.

OUTLOOK

According to the Government of India, rice output is expected to decline to 69.45 mn tonnes as compared to an output of 84.5 mn tonnes last year. Although India has stock reserves of ~6 mn tones, *it is going to face a deficit of ~15 mn tonnes*. The biggest hit is taken by average quality rice in Punjab and Haryana on account of poor rains which has affected market sentiments adversely and impacted rice prices.

arm research



outperform

Disclaimer

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients and Associates of arm research. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable though its accuracy or completeness cannot be guaranteed. Neither arm research, nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We and our affiliates, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. No part of this material may be duplicated in any form and/or redistributed without arm research's prior written consent.